Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ: NEO )

10.43 +0.03 (+0.29%)
Streaming Delayed Price Updated: 10:41 AM EST, Feb 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
The Law Offices of Frank R. Cruz Announces Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of NeoGenomics, Inc. (NEO) Investors
From Kirby McInerney LLP
Via Business Wire
Mid-Afternoon Market Update: Dow Surges 250 Points; NeoGenomics Shares Slide
U.S. stocks traded higher toward the end of trading, with the Dow jumping over 250 points on Tuesday. 
Via Benzinga
Why Is NeoGenomics (NEO) Stock Down Today?
Cancer-testing company NeoGenomics is down more than 30% today after lowering earnings expectations. How far will NEO stock fall? 
Via InvestorPlace
NeoGenomics Stock Gets Downgrade After CEO Resigns And Other Negative Updates
NeoGenomics, Inc. 
Via Benzinga
NeoGenomics Stock Tanks After CEO Exits Amid Sales, Profitability Maelstrom
Shares were hammered after NeoGenomics pulled its full-year outlook. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers IGM Biosciences (NASDAQ:IGMS) shares rose 114.8% to $32.2 during Tuesday's regular session. IGM Biosciences's stock is trading at a volume of 31.6 million... 
Via Benzinga
Stocks Higher as Ukraine-Russia Peace Talks Advance
Optimism is high on Wall Street, as peace talks between Ukraine and Russia seem to advance. 
Via Talk Markets
Mid-Day Market Update: Crude Oil Down 2.5%; IGM Biosciences Shares Jump
U.S. stocks traded higher midway through trading, with the Dow jumping over 250 points on Tuesday. 
Via Benzinga
Twilio Insider Trading Scandal: 8 Things for TWLO Stock Investors to Know
Twilio (TWLO) stock is on the move Tuesday as the U.S. Securities and Exchange Commission (SEC) weighs in on an insider trading scandal. 
Via InvestorPlace
Why NeoGenomics Stock Is Plunging Today
Via Benzinga
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) jumped 88.1% to $0.38 after declining 9% on Monday. McCormick (NASDAQ: IGMS) shares jumped 49.8% to $22.46. Sanofi SA (... 
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in NeoGenomics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Mid-Morning Market Update: Markets Open Higher; McCormick Profit Beats Estimates
U.S. stocks opened on a strong note on Tuesday, with the Dow jumping around 350 points this morning. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 81 stocks hit new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Grupo Aval Acciones (NYSE:AVAL) was the biggest company by market cap to set a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2022
Upgrades 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
BTIG cut the price target on NeoGenomics, Inc. (NASDAQ: NEO) from $35 to $28. NeoGenomics shares fell 29.2% to $12.60 in pre-market trading. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock moved upwards by 45.0% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $8.5 million. 
Via Benzinga
Where NeoGenomics Stands With Analysts
Over the past 3 months, 8 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) rose 40.1% to $21.00 in pre-market trading following announcement of collaboration with Sanofi (NASDAQ: SNY). Guardforce AI Co.,... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time to start another busy day of trading with another breakdown of the biggest pre-market stock movers on Tuesday! 
Via InvestorPlace
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in NeoGenomics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ALERT - Labaton Sucharow Investigating NeoGenomics Inc. - NEO
From Labaton Sucharow LLP
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers NexImmune (NASDAQ:NEXI) stock moved upwards by 8.3% to $3.51 during Monday's after-market session. This security traded at a volume of 109.1K shares come close, making up 76.6% of its average... 
Via Benzinga
NeoGenomics Announces CEO Departure and Initiates CEO Search
Board Appoints Executive Chair and Interim Office of the CEO Anticipates First Quarter Results Below Guidance and Withdraws 2022 Guidance FT. MYERS, FL / ACCESSWIRE / March 28, 2022 / NeoGenomics, Inc.... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay in Non-Small Cell Lung Cancer
Study further highlights potential of RaDaR to stratify patients and improve treatment outcomes FT. MYERS, FL / ACCESSWIRE / March 17, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Earnings Perspective: Return On Capital Employed
NeoGenomics (NASDAQ:NEO) brought in sales totaling $125.73 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 105.22%, resulting in a loss... 
Via Benzinga
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
FT MYERS, FL / ACCESSWIRE / March 2, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced... 
From NeoGenomics, Inc.
Via AccessWire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.